<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783847</url>
  </required_header>
  <id_info>
    <org_study_id>90-01-124-12972</org_study_id>
    <nct_id>NCT01783847</nct_id>
  </id_info>
  <brief_title>Traumatic Optic Neuropathy Treatment Trial (TONTT)</brief_title>
  <acronym>TONTT</acronym>
  <official_title>Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology of Traumatic Optic Neuropathy (TON) is thought to be multifactorial, and
      some researchers have also postulated a primary and secondary mechanism of injury.TON is
      categorized as direct or indirect.In indirect TON cases, the injury to the axons is thought
      to be induced by shearing forces that are transmitted to the fibers or to the vascular supply
      of the nerve. Studies have shown that forces applied to the frontal bone and malar eminences
      are transferred and concentrated in the area near the optic canal. The tight adherence of the
      optic nerve's dural sheath to the periosteum within the optic canal is also thought to
      contribute to this segment of the nerve being extremely susceptible to the deformative
      stresses of the skull bones. Such injury leads to ischemic injury to the axons of the retinal
      ganglion cells within the optic canal. At present, no studies validate a particular approach
      to the management of TON. There are three management lines for these patients that include
      1)observation only;2)medical treatment with high or megadoses of methylprednisolone; and
      3)surgical intervention. Generally no line precedes the others and additionally, medical or
      surgical interventions may result in serious side effects or complications. In 2005, the
      results of the Corticosteroid Randomization after Significant Head Injury (CRASH) trial
      raised concerns regarding the use of mega dose steroids in traumatic brain injury. This study
      was the largest randomized study that evaluated steroids in patients with traumatic brain
      injury and was stopped early due to the significantly increased risk of death in patients
      that received mega dose steroids at their 6-month follow-up when compared with the placebo
      group (25.7% vs 22.3%; Relative Risk 1.15 Confidence Interval 1.07 to 1.24; p=0.0001).
      Although the etiology of the increased risk of death was not determined, the findings of this
      study should be taken into consideration when managing cases of TON with concurrent traumatic
      brain injury. Very recently it has been shown the cytokine hormone erythropoietin (EPO) that
      had been long known and used as a valuable agent to promote hematopoiesis has been protective
      in experimental models of mechanical trauma, neuroinflammation, cerebral and retinal
      ischemia, and even in a human stroke trial, and most notably in optic nerve transection. A
      double blind placebo-controlled multicenter trial on EPO add-on treatment in chronic
      schizophrenic men was performed. Treatment over 12 weeks with high-dose weekly (40,000 IU
      intravenously) EPO led to significant improvement of cognitive performance compared to
      placebo controls. Different studies have been performed on the effect of EPO on neuropathy in
      different studies. The investigators recently published our results on treating patients with
      TON with EPO and found it safe and effective. Patients were compared with a historical
      control group of patients who received no treatment for TON. A better visual recovery was
      found. The aim of this study is to determine the effectiveness of EPO on TON in a Multi-
      center clinical trial using a semi-experimental design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Change/Improvement Visual Acuity From the Beseline</measure>
    <time_frame>Change from baseline at least 3 months after treatment</time_frame>
    <description>Best corrected visual acuity will measure at 1,2,3 days, 1 week, 2 weeks and 1 month and at least 3 months after treatment. Improvement is defined based on 1) mean logMAR[12], 2) 0.3 change in logMAR (improvement, deterioration, and no change) [12,16] , 3) mean improvement percentage which is calculated as: improvement%= (logMar ( of VA after treatment)-logMar ( of initial VA))/(logMar(20/13)˟-logMar ( of initial VA) 4) percentage of patients at different ordinal categorization of the BCVA as no light perception (NLP), light perception (LP)and hand motion (HM), count fingers (CF), and ≥ 20/200.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Relative Afferent Papillary Defect (RAPD) Grade +4</measure>
    <time_frame>Change from baseline at least 3 months after treatment</time_frame>
    <description>A positive RAPD means there are differences between the two eyes in the afferent pathway due to retinal or optic nerve disease. Graded from +1 to +4. The higher one is a better grade</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Traumatic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Recombinant human erythropoietin (EPO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous EPO 10,000 IU for 5-13 years of age and 20,000 IU for &gt;13 years/ day for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Just Intravenous Methyl prednisolone 250 mg every 6 hours for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human erythropoietin (EPO)</intervention_name>
    <description>4000 units per vial</description>
    <arm_group_label>Recombinant human erythropoietin (EPO)</arm_group_label>
    <other_name>EPO (Pooyesh darou Co., Tehran)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Just observation</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl prednisolone</intervention_name>
    <description>250 mg every 6 hours for 3 days.</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>Depo-Medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having indirect traumatic optic neuropathy, not more than 3 weeks between trauma and
             treatment, normal fundoscopy

        Exclusion Criteria:

          -  Having other injuries that effect on visual function, direct optic neuropathy,
             glaucoma, diabetic retinopathy, uncontrolled hypertension, polycythemia, creatinin
             more than 3 mg/dl, sensitivity to EPO, hyperkalemia, women who use contraceptive pill,
             pregnant and breast feeding women, history of stroke and cardiovascular diseases,
             having malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohsen B Kashkouli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Iran University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <zip>1467744814</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beheshti University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>February 1, 2013</study_first_submitted>
  <study_first_submitted_qc>February 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <results_first_submitted>April 7, 2017</results_first_submitted>
  <results_first_submitted_qc>September 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 12, 2018</results_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>Traumatic Optic Neuropathy</keyword>
  <keyword>Visual function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Nerve Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Recombinant Human Erythropoietin (EPO)</title>
          <description>20,000 unit per day of EPO, Intravenous infusion for three sequential days.
Recombinant human erythropoietin (EPO): 4000 units per vial</description>
        </group>
        <group group_id="P2">
          <title>Methylprednisolone</title>
          <description>250 mg intravenous injection of Methylprednisolone for 3 days.</description>
        </group>
        <group group_id="P3">
          <title>Observation</title>
          <description>No any treatment will be given</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Recombinant Human Erythropoietin (EPO)</title>
          <description>20,000 unit per day of EPO, Intravenous infusion for three sequential days.
Recombinant human erythropoietin (EPO): 4000 units per vial</description>
        </group>
        <group group_id="B2">
          <title>Methylprednisolone</title>
          <description>1 gram per day intravenous injection of Methylprednisolone for 3 days.</description>
        </group>
        <group group_id="B3">
          <title>Observation</title>
          <description>No any treatment will be given</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.4" spread="13.9"/>
                    <measurement group_id="B2" value="23.5" spread="9.4"/>
                    <measurement group_id="B3" value="29.0" spread="13.7"/>
                    <measurement group_id="B4" value="27.8" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran, Islamic Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Change/Improvement Visual Acuity From the Beseline</title>
        <description>Best corrected visual acuity will measure at 1,2,3 days, 1 week, 2 weeks and 1 month and at least 3 months after treatment. Improvement is defined based on 1) mean logMAR[12], 2) 0.3 change in logMAR (improvement, deterioration, and no change) [12,16] , 3) mean improvement percentage which is calculated as: improvement%= (logMar ( of VA after treatment)-logMar ( of initial VA))/(logMar(20/13)˟-logMar ( of initial VA) 4) percentage of patients at different ordinal categorization of the BCVA as no light perception (NLP), light perception (LP)and hand motion (HM), count fingers (CF), and ≥ 20/200.</description>
        <time_frame>Change from baseline at least 3 months after treatment</time_frame>
        <population>Seventeen patients with incomplete follow up and not following the treatment protocol were also excluded during the study. There were 100 patients (100 eyes) who completed the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Erythropoietin (EPO)</title>
            <description>Intravenous EPO 10,000 IU for 5-13 years of age and 20,000 IU for &gt;13 years/ day for 3 days
Recombinant human erythropoietin (EPO): 4000 units per vial</description>
          </group>
          <group group_id="O2">
            <title>Methylprednisolone</title>
            <description>Just Intravenous Methyl prednisolone 250 mg every 6 hours for 3 days.
Methyl prednisolone: 250 mg every 6 hours for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>Observation
Observation: Just observation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change/Improvement Visual Acuity From the Beseline</title>
          <description>Best corrected visual acuity will measure at 1,2,3 days, 1 week, 2 weeks and 1 month and at least 3 months after treatment. Improvement is defined based on 1) mean logMAR[12], 2) 0.3 change in logMAR (improvement, deterioration, and no change) [12,16] , 3) mean improvement percentage which is calculated as: improvement%= (logMar ( of VA after treatment)-logMar ( of initial VA))/(logMar(20/13)˟-logMar ( of initial VA) 4) percentage of patients at different ordinal categorization of the BCVA as no light perception (NLP), light perception (LP)and hand motion (HM), count fingers (CF), and ≥ 20/200.</description>
          <population>Seventeen patients with incomplete follow up and not following the treatment protocol were also excluded during the study. There were 100 patients (100 eyes) who completed the study protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Relative Afferent Papillary Defect (RAPD) Grade +4</title>
        <description>A positive RAPD means there are differences between the two eyes in the afferent pathway due to retinal or optic nerve disease. Graded from +1 to +4. The higher one is a better grade</description>
        <time_frame>Change from baseline at least 3 months after treatment</time_frame>
        <population>Seventeen patients dropped out of the study due to incomplete follow-up (16 patients from EPO and one patient from Methylprednisolone group)</population>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Erythropoietin (EPO)</title>
            <description>20,000 unit per day of EPO, Intravenous infusion for three sequential days.
Recombinant human erythropoietin (EPO): 4000 units per vial</description>
          </group>
          <group group_id="O2">
            <title>Methylprednisolone</title>
            <description>250 mg intravenous injection of Methylprednisolone for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>No any treatment will be given</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Relative Afferent Papillary Defect (RAPD) Grade +4</title>
          <description>A positive RAPD means there are differences between the two eyes in the afferent pathway due to retinal or optic nerve disease. Graded from +1 to +4. The higher one is a better grade</description>
          <population>Seventeen patients dropped out of the study due to incomplete follow-up (16 patients from EPO and one patient from Methylprednisolone group)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Recombinant Human Erythropoietin (EPO)</title>
          <description>20,000 unit per day of EPO, Intravenous infusion for three sequential days.
Recombinant human erythropoietin (EPO): 4000 units per vial</description>
        </group>
        <group group_id="E2">
          <title>Methylprednisolone</title>
          <description>250 mg intravenous injection of Methylprednisolone for 3 days.</description>
        </group>
        <group group_id="E3">
          <title>Observation</title>
          <description>No any treatment will be given</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mohsen Bahmani Kashkouli</name_or_title>
      <organization>Iran university of Medical Sciences</organization>
      <phone>00989121777003</phone>
      <email>mkashkouli2@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

